58 INOVIQ Limited The Group’s non-current assets are located in the following geographic regions: As at 30 June 2022 $ As at 30 June 2021 $ Australia (domicile) 12,574,009 27,395,277 United States of America 622,429 386,195 Switzerland - 91,703 Total 13,196,438 27,873,175 20 DIRECTORS & KEY MANAGEMENT PERSONNEL For the year ended 30 June 2022 $ For the year ended 30 June 2021 $ (a) Compensation by Category: Key Management Personnel Short-term employee benefits 1,253,303 1,468,787 Post-employment benefits 95,407 106,562 Share based payments 304,260 628,732 Other long term benefits 20,238 16,565 1,673,208 2,220,646 Key management personnel (KMP) are those directly accountable and responsible for the operational management and strategic direction of the Company and the Group. The KMP during the year were: – Dr Geoffrey Cumming (appointed 28 July 2020) – Mr Philip Powell (appointed 17 June 2019) – Mr Max Johnston (appointed 17 June 2019) – Professor Allan Cripps (appointed 23 January 2020) – Dr Leearne Hinch (appointed 7 November 2016) – Mr Tony Di Pietro (appointed 28 July 2020) – Dr Gregory Rice (appointed 20 September 2021) – Dr Peter French (appointed 17 August 2020, resigned 17 August 2021, transitioned to the role of Strategic Technology Advisor under a consultancy agreement) – Mr Carl Stubbings (appointed 28 July 2020, resigned 31 August 2021) (b) Options granted to Key Management Personnel During the 2022 financial year: – 500,000 options were issued to Chairman, Dr Geoffrey Cumming under the Company’s Incentive Option Plan; – 500,000 options were issued to Director, Max Johnston, under the Company’s Incentive Option Plan; – 500,000 options were issued to Director, Philip Powell, under the Company’s Incentive Option Plan; – 500,000 options were issued to Director, Professor Allan Cripps, under the Company’s Incentive Option Plan; – 150,000 options were issued to CSO, Dr Gregory Rice, under the Company’s Incentive Option Plan. – 50,000 options were issued to Strategic Technology Advisor, Dr Peter French, under the Company’s Incentive Option Plan. All options on issue are subject to the terms and conditions of the Company’s Incentive Option Plan. Details of options on issue are set out in Note 21. (c) Loans to/ amounts owed to Key Management Personnel There were no loans to KMP or amounts owed to KMP’s at 30 June 2022 (2021: nil). (d) Consulting fees paid/owed to Key Management Personnel After ceasing his role as Chief Scientific Officer on 17 August 2021, Dr Peter French received $42,400 under a consultancy agreement during the reporting period, for strategic technology advice. There were no other consulting fees paid to KMP’s during the financial year. 19 SEGMENT INFORMATION (CONTINUED) Notes to the Financial Statements for the year ended 30 June 2022
RkJQdWJsaXNoZXIy MjE2NDg3